IL9 and melanoma: Upon studying the mechanism responsible for the anti-tumor activity of TH9 cells in melanoma, the authors found, in contrast to published studies in hematological cancers, that IL-9 blockade using neutralizing antibodies prevented the beneficial effect of adoptive TH9 cell transfer, underscoring the anti-tumor role for IL-9 in this setting.